Navigation Links
Lilly Receives NCQA Design Certification for Depression Care Management Program
Date:11/6/2007

INDIANAPOLIS, Nov. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has received Program Design Certification from the National Committee for Quality Assurance (NCQA) for its Tools that Empower(TM) Depression Care Management Program.

Tools that Empower(TM) Depression Care Management Program is designed for managed care organizations to assist in further driving the standard of patient care around Major Depressive Disorder (MDD). Lilly created the program in response to the growing population of patients diagnosed with MDD.

Developed by experts in MDD management, including practicing psychiatrists and psychologists, clinical research experts, managed care medical directors and mental health specialty physicians, Tools that Empower helps identify members with MDD and offers educational resources to support treatment. In addition, the program helps enroll members, perform clinical screening and clinical risk stratification; offers interventions based on member clinical risk; executes program satisfaction assessment and outcomes measurement; and provides a comprehensive list of MDD resources.

The foundation of this program is based upon the APA Standards of Care for major depressive disorder, the HEDIS(R) measure for Antidepressant Medication Management, and several other related, peer-reviewed articles.

NCQA certification is an indication that a disease management program has passed a rigorous review in a specific area, either program design, patient contact or disease management systems. According to NCQA, certification standards are purposely set high to encourage organizations to continuously enhance their quality.

"Disease management offers tremendous promise for improving th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 1AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 1Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 3PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 1PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 2
Other Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10